Literature DB >> 21791360

Human papillomavirus type 16 E6 inhibits p21(WAF1) transcription independently of p53 by inactivating p150(Sal2).

Peggy Parroche1, Majid Touka, Mariam Mansour, Véronique Bouvard, Amélie Thépot, Rosita Accardi, Christine Carreira, Guillaume G Roblot, Bakary S Sylla, Uzma Hasan, Massimo Tommasino.   

Abstract

HPV16 E6 deregulates G1/S cell cycle progression through p53 degradation preventing transcription of the CDK inhibitor p21(WAF1). However, additional mechanisms independent of p53 inactivation appear to exist. Here, we report that HPV16 E6 targets the cellular factor p150(Sal2), which positively regulates p21(WAF1) transcription. HPV16 E6 associates with p150(Sal2), inducing its functional inhibition by preventing its binding to cis elements on the p21(WAF1) promoter. A HPV16 E6 mutant, L110Q, which was unable to bind p150(Sal2), did not affect the ability of the cellular protein to bind p21(WAF1) promoter, underlining the linkage between these events. These data describe a novel mechanism by which HPV16 E6 induces cell cycle deregulation with a p53-independent pathway. The viral oncoprotein targets p150(Sal2), a positive transcription regulator of p21(WAF1) gene, preventing G1/S arrest and allowing cellular proliferation and efficient viral DNA replication.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21791360     DOI: 10.1016/j.virol.2011.05.016

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  11 in total

1.  Human papillomavirus 16E6 and NFX1-123 potentiate Notch signaling and differentiation without activating cellular arrest.

Authors:  Portia A Vliet-Gregg; Jennifer R Hamilton; Rachel A Katzenellenbogen
Journal:  Virology       Date:  2015-02-25       Impact factor: 3.616

Review 2.  Infection, mutation, and cancer evolution.

Authors:  Paul W Ewald; Holly A Swain Ewald
Journal:  J Mol Med (Berl)       Date:  2012-04-04       Impact factor: 4.599

3.  The scope of viral causation of human cancers: interpreting virus density from an evolutionary perspective.

Authors:  Paul W Ewald; Holly A Swain Ewald
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-05-27       Impact factor: 6.237

Review 4.  The tumor suppressor protein p150(Sal2) in carcinogenesis.

Authors:  Chang Kyoo Sung; Hyungshin Yim
Journal:  Tumour Biol       Date:  2015-01-22

Review 5.  Molecular Mechanisms of HIV Protease Inhibitors Against HPV-Associated Cervical Cancer: Restoration of TP53 Tumour Suppressor Activities.

Authors:  Lilian Makgoo; Salerwe Mosebi; Zukile Mbita
Journal:  Front Mol Biosci       Date:  2022-05-10

6.  The polyoma virus large T binding protein p150 is a transcriptional repressor of c-MYC.

Authors:  Chang Kyoo Sung; Hyungshin Yim; Hongcang Gu; Dawei Li; Erik Andrews; Sekhar Duraisamy; Cheng Li; Ronny Drapkin; Thomas Benjamin
Journal:  PLoS One       Date:  2012-09-28       Impact factor: 3.240

7.  The differential role of HTRA1 in HPV-positive and HPV-negative cervical cell line proliferation.

Authors:  Bruna Stuqui; André Luis Giacometti Conceição; Lara Termini; Laura Sichero; Luisa Lina Villa; Paula Rahal; Marília de Freitas Calmon
Journal:  BMC Cancer       Date:  2016-11-03       Impact factor: 4.430

8.  Effect of siRNA-silencing of SALL2 gene on growth, migration and invasion of human ovarian carcinoma A2780 cells.

Authors:  Fang Miao; Xueshan Zhang; Yanning Cao; Yue Wang; Xiaoshu Zhang
Journal:  BMC Cancer       Date:  2017-12-11       Impact factor: 4.430

9.  SALL2 represses cyclins D1 and E1 expression and restrains G1/S cell cycle transition and cancer-related phenotypes.

Authors:  Viviana E Hermosilla; Ginessa Salgado; Elizabeth Riffo; David Escobar; Matías I Hepp; Carlos Farkas; Mario Galindo; Violeta Morín; María A García-Robles; Ariel F Castro; Roxana Pincheira
Journal:  Mol Oncol       Date:  2018-05-21       Impact factor: 6.603

10.  Wild type p53 transcriptionally represses the SALL2 transcription factor under genotoxic stress.

Authors:  Carlos Farkas; Carla P Martins; David Escobar; Matias I Hepp; Ariel F Castro; Gerard Evan; José L Gutiérrez; Robert Warren; David B Donner; Roxana Pincheira
Journal:  PLoS One       Date:  2013-09-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.